SERUM OSTEOCALCIN AND VITAMIN-D METABOLITES IN PATIENTS WITH ANKYLOSING-SPONDYLITIS

被引:59
作者
FRANCK, H [1 ]
KECK, E [1 ]
机构
[1] DEPT RHEUMATOL 2,WIESBADEN,GERMANY
关键词
D O I
10.1136/ard.52.5.343
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives-Osteocalcin is the major non-collagenous protein of bone and is regarded as a specific index of bone formation. The aim of this study was to examine the rate of bone formation measured by osteocalcin in 38 patients with ankylosing spondylitis (AS) and its dependence on various parameters of calcium and phosphate metabolism. Methods-Serum osteocalcin, alkaline phosphatase, parathyroid hormone, and 1,25-dihydroxyvitamin D were measured in 38 patients with ankylosing spondylitis and in 52 controls. Results-Mean serum osteocalcin was significantly reduced in patients with AS (men 1.7 (1.1) ng/ml; women 1.2 (1-1) ng/ml) compared with the corresponding control groups (men 3.2 (1.3) ng/ml; women 4.1 (1.7) ng/ml). In contrast, alkaline phosphatase was only slightly but significantly higher (135 (44) U/l) in patients with AS than in the corresponding controls (114 (35) U/l). Serum parathyroid hormone (AS 3.1 (0.7) v 2.7 (0.6) mE/ml) and 1,25-dihydroxyvitamin D (AS 64.0 (34.S) v S2.4 (6.7) pg/ml) were slightly but not significantly higher in patients with AS. Consequently, as both hormones are known to stimulate osteocalcin synthesis, they are not responsible for low osteocalcin levels in patients with AS. No significant correlation between alkaline phosphatase and osteocalcin was found. Low serum levels of osteocalcin in patients with AS reflect lower osteoblastic activity in AS. Conclusions-Bone turnover in patients with AS is characterised by low bone formation in the presence of normal levels of calcium regulating hormones.
引用
收藏
页码:343 / 346
页数:4
相关论文
共 25 条
[1]   PRODUCTION OF OSTEOCALCIN BY HUMAN-BONE CELLS-INVITRO - EFFECTS OF 1,25(OH)2D3, 24,25(OH)2D3, PARATHYROID-HORMONE, AND GLUCOCORTICOIDS [J].
BERESFORD, JN ;
GALLAGHER, JA ;
POSER, JW ;
RUSSELL, RGG .
METABOLIC BONE DISEASE & RELATED RESEARCH, 1984, 5 (05) :229-234
[2]   BONE GLA PROTEIN IN PREDIALYSIS CHRONIC-RENAL-FAILURE - EFFECTS OF 1,25(OH)2D3 ADMINISTRATION IN A LONG-TERM FOLLOW-UP [J].
COEN, G ;
MAZZAFERRO, S ;
BONUCCI, E ;
TAGGI, F ;
BALLANTI, P ;
BIANCHI, AR ;
DONATO, G ;
MASSIMETTI, C ;
SMACCHI, A ;
CINOTTI, GA .
KIDNEY INTERNATIONAL, 1985, 28 (05) :783-790
[3]   CHANGES IN PLASMA BONE GLA PROTEIN DURING TREATMENT OF BONE-DISEASE [J].
DEFTOS, LJ ;
PARTHEMORE, JG ;
PRICE, PA .
CALCIFIED TISSUE INTERNATIONAL, 1982, 34 (02) :121-124
[4]   EFFECT OF RENAL-FUNCTION ON PLASMA-LEVELS OF BONE GLA-PROTEIN [J].
DELMAS, PD ;
WILSON, DM ;
MANN, KG ;
RIGGS, BL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 57 (05) :1028-1030
[5]  
DELMAS PD, 1984, ENDOCRINE CONTROL BO, P73
[6]  
DIXON WJ, 1969, INTRO STATISTICAL AN
[7]   SERUM OSTEOCALCIN IN RHEUMATOID-ARTHRITIS AND OTHER INFLAMMATORY ARTHRITIDES - RELATION BETWEEN INFLAMMATORY ACTIVITY AND THE EFFECT OF GLUCOCORTICOIDS AND REMISSION INDUCING DRUGS [J].
EKENSTAM, EA ;
LJUNGHALL, S ;
HALLGREN, R .
ANNALS OF THE RHEUMATIC DISEASES, 1986, 45 (06) :484-490
[8]  
FRANCK H, 1986, Z RHEUMATOL, V45, P241
[9]  
HANSON CA, 1971, CLIN ORTHOP RELAT R, V74, P59
[10]  
KECK E, 1981, J CLIN CHEM CLIN BIO, V19, P1043